FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Swedish Court Delays Judgment in Klarna’s Antitrust Case Against Google

The court's decision is crucial for Klarna's operations in the competitive market.Highlights: Swedish court delays decision on Klarna's...
FinTech

Morgan Stanley Launches Bitcoin ETF, Expanding Crypto Offerings

The investment firm broadens its reach into the cryptocurrency market.Highlights: Morgan Stanley launches a Bitcoin ETF to enhance...
FinTech

HSBC Strengthens Position with Hong Kong Stablecoin Issuer License

The banking giant aims to support digital asset initiatives in the region.Highlights: HSBC receives a stablecoin issuer license...
FinTech

US Treasury Secretary Warns Banks About Anthropic’s New AI Model

Treasury Secretary highlights risks AI poses to financial stability.Highlights: US Treasury Secretary warns banks about the risks of...